Key result
Cardiomyopathy in pregnancy is linked to increased adverse maternal outcomes including death.
Why the study?
This study aimed to systematically assess the impact of cardiomyopathy on maternal pregnancy outcomes.
Does the presence of cardiomyopathy impact maternal pregnancy outcomes in pregnant women?
Meta-Analysis
Does the presence of cardiomyopathy impact maternal pregnancy outcomes in pregnant women?
Pregnant women with cardiomyopathy are at significantly increased risk for adverse maternal outcomes, including death, highlighting the need for preconception risk assessment and multidisciplinary care.
Answers are grounded in this paper and cite their sources.
Supports preconception counseling and multidisciplinary care in cardiomyopathy pregnancies; confirms elevated maternal mortality risk via meta-analysis.
OBJECTIVE: This study aimed to systematically assess the impact of cardiomyopathy on maternal pregnancy outcomes. DATA SOURCES: PubMed, Ovid Embase, Ovid MEDLINE, Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to April 24, 2022. STUDY ELIGIBILITY CRITERIA: Observational cohort, case-control, and case-cohort studies in human populations were included if they reported predefined maternal outcomes for pregnant women with cardiomyopathy (any subtype) and for an appropriate control population (pregnant women with no known heart disease or pregnant women with noncardiomyopathy heart disease). METHODS: Two reviewers independently assessed the articles for eligibility and risk of bias, and conflicts were resolved by a third reviewer. Data were extracted and synthesized according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analyses of Observational Studies in Epidemiology guidelines. CONCLUSION: Pregnant women with cardiomyopathy have increased risks for adverse maternal outcomes, including maternal death, when compared with both women with no heart disease and women with noncardiomyopathy heart disease. Our results highlight the importance of preconception risk assessments to allow for informed decision-making before pregnancy. Pregnancies affected by cardiomyopathy are high risk and should be managed by expert, multidisciplinary obstetrical and cardiology teams.
No takes yet. Share an insight, caveat, or question.
Eggleton et al. (2022) conducted a meta-analysis in Cardiomyopathy in pregnancy. Cardiomyopathy vs. No known heart disease or noncardiomyopathy heart disease was evaluated on Adverse maternal outcomes (p=<.00001). Pregnant women with cardiomyopathy have increased risks for adverse maternal outcomes, including maternal death, compared with women without cardiomyopathy (P<.00001).
Synapse has enriched 10 related papers. Consider them for comparative context: